Shares of major vaccine manufacturers, including Moderna, Novavax, and BioNTech, fell in premarket trading following the announcement of Robert F. Kennedy Jr. as the prospective Secretary of Health and Human Services under President-elect Donald Trump.

Kennedy’s skepticism of mass vaccinations and his commitment to addressing America’s chronic disease epidemic has raised concerns among pharmaceutical executives. The declines in stock prices were noted both in the U.S. and among European companies like Sanofi and GSK. Analysts speculate that Kennedy’s potential influence could disrupt established relationships between Big Pharma and government agencies, particularly regarding vaccine oversight.

While there are questions about Kennedy’s confirmation, some believe a recess appointment is feasible. The media has previously portrayed Kennedy favorably, including discussions of his potential role in the Obama administration.

Kennedy’s skepticism regarding vaccinations may lead to changes in regulatory practices, potentially affecting vaccine approvals and public health strategies.

Investors are concerned that Kennedy’s perspective on vaccines could threaten the established connections between pharmaceutical companies and government agencies, impacting future profitability.

Please follow and like us: